About this Research Topic
Coronaviruses (CoVs) are named for the crown-like spikes on their surface. They belong to the Nidovirales order, which includes Arteriviridae Roniviridae, Mesoniviridae, and Coronaviridae families. Four main sub-groups of CoVs are known; alpha, beta, gamma, and delta. In the mid-1960s, human coronaviruses were first identified. Currently seven human coronaviruses are known: HKU1 (beta coronavirus), OC43 (beta coronavirus), NL63 (alpha coronavirus), 229E (alpha coronavirus), MERS-CoV (beta coronavirus), SARS-CoV (beta coronavirus), and SARS-CoV-2. The latter is the novel beta coronavirus that causes a severe acute respiratory syndrome known as coronavirus disease 2019 (COVID-19). The COVID-19 pandemic is accelerating around the world – it took four months to reach around 3,000,000 cases and subsequently less than two months to increase to over 8,500,000 confirmed cases.
The goal of this Research Topic is to cover recent and novel research trends in the field of finding and synthesizing therapeutics and vaccines for COVID-19 pandemic. Another aim is to investigate the attachment and cell entry mechanism of SARS-CoV-2. This Research Topic is intended to become an international platform for researchers to summarize the most recent developments and ideas in the field of therapeutics and vaccines for the COVID-19 pandemic, with special emphasis on small molecules and peptide-based candidates and their roles as therapeutics and vaccines. We welcome original research articles and reviews that cover areas including but not limited to:
• Synthesis of potential small molecules and peptide-based candidates as therapeutics or vaccines for the COVID-19 pandemic
• Multiple antigenic peptide (MAP) strategies for diagnostics, therapeutics, and vaccination
• Studies on the attachment and cell entry mechanism of SARS-CoV-2
• Studies on current drugs with potential for treatment of COVID-19
Topic Editor Dr. Balakumar Chandrasekaran holds patents relating to N-substituted isatin hydrazones as antimycobacterial and antimicrobial agents, and Pharmaceutical Compounds. Topic Editor Dr. Munir Al-Zeer holds a patent relating to Method for the Preparation of an Influenza Virus. All other Topic Editors declare no competing interests.
The goal of this Research Topic is to cover recent and novel research trends in the field of finding and synthesizing therapeutics and vaccines for COVID-19 pandemic. Another aim is to investigate the attachment and cell entry mechanism of SARS-CoV-2. This Research Topic is intended to become an international platform for researchers to summarize the most recent developments and ideas in the field of therapeutics and vaccines for the COVID-19 pandemic, with special emphasis on small molecules and peptide-based candidates and their roles as therapeutics and vaccines. We welcome original research articles and reviews that cover areas including but not limited to:
• Synthesis of potential small molecules and peptide-based candidates as therapeutics or vaccines for the COVID-19 pandemic
• Multiple antigenic peptide (MAP) strategies for diagnostics, therapeutics, and vaccination
• Studies on the attachment and cell entry mechanism of SARS-CoV-2
• Studies on current drugs with potential for treatment of COVID-19
Topic Editor Dr. Balakumar Chandrasekaran holds patents relating to N-substituted isatin hydrazones as antimycobacterial and antimicrobial agents, and Pharmaceutical Compounds. Topic Editor Dr. Munir Al-Zeer holds a patent relating to Method for the Preparation of an Influenza Virus. All other Topic Editors declare no competing interests.
Keywords: SARS-CoV-2, COVID-19, Multiple antigenic peptide, Vaccines
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
